Deutsche Bank AG Purchases 73,912 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Deutsche Bank AG boosted its position in Janux Therapeutics, Inc. (NASDAQ:JANX) by 386.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 93,029 shares of the company’s stock after buying an additional 73,912 shares during the quarter. Deutsche Bank AG owned approximately 0.18% of Janux Therapeutics worth $4,981,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of JANX. Lester Murray Antman dba SimplyRich boosted its holdings in Janux Therapeutics by 205.3% during the fourth quarter. Lester Murray Antman dba SimplyRich now owns 24,315 shares of the company’s stock valued at $1,301,000 after acquiring an additional 16,351 shares during the period. abrdn plc acquired a new position in shares of Janux Therapeutics during the 4th quarter worth about $3,430,000. Barclays PLC boosted its stake in Janux Therapeutics by 496.5% during the 3rd quarter. Barclays PLC now owns 174,061 shares of the company’s stock valued at $7,907,000 after purchasing an additional 144,883 shares during the period. Legal & General Group Plc grew its holdings in Janux Therapeutics by 45.3% in the 4th quarter. Legal & General Group Plc now owns 34,540 shares of the company’s stock valued at $1,849,000 after buying an additional 10,776 shares during the last quarter. Finally, Rhumbline Advisers increased its position in Janux Therapeutics by 1.6% in the 4th quarter. Rhumbline Advisers now owns 38,153 shares of the company’s stock worth $2,043,000 after buying an additional 599 shares during the period. Institutional investors own 75.39% of the company’s stock.

Insider Activity

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,333 shares of the business’s stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $32.03, for a total value of $106,755.99. Following the transaction, the insider now directly owns 82,139 shares in the company, valued at $2,630,912.17. The trade was a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ra Capital Management, L.P. acquired 341,742 shares of the firm’s stock in a transaction on Wednesday, March 5th. The shares were purchased at an average cost of $30.64 per share, for a total transaction of $10,470,974.88. Following the completion of the purchase, the director now directly owns 9,658,988 shares of the company’s stock, valued at approximately $295,951,392.32. The trade was a 3.67% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 10,001 shares of company stock worth $313,964. Company insiders own 8.10% of the company’s stock.

Janux Therapeutics Stock Performance

Shares of JANX stock opened at $24.28 on Monday. The firm has a fifty day moving average of $28.66 and a 200-day moving average of $40.54. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of -20.75 and a beta of 3.24. Janux Therapeutics, Inc. has a 52-week low of $22.48 and a 52-week high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, sell-side analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Analyst Ratings Changes

JANX has been the subject of several research reports. Scotiabank reduced their price objective on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a research report on Friday, February 28th. Wedbush reissued an “outperform” rating and issued a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Finally, HC Wainwright restated a “buy” rating and issued a $70.00 price target on shares of Janux Therapeutics in a research report on Monday, March 3rd. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $95.25.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.